Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results
August 08, 2018 07:00 ET
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business...
Leap Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors
July 23, 2018 07:30 ET
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has...
Leap Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference
June 13, 2018 07:00 ET
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
Leap Therapeutics Reports First Quarter 2018 Financial Results
May 11, 2018 07:00 ET
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial...
Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting
April 16, 2018 09:00 ET
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented nonclinical and clinical data on DKN-01, Leap’s anti-DKK1 monoclonal antibody, at the...
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 27, 2018 16:05 ET
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock
March 23, 2018 09:00 ET
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
Leap Therapeutics Announces Proposed Public Offering of Common Stock
March 22, 2018 16:05 ET
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference
March 21, 2018 07:00 ET
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., March 21, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
March 14, 2018 17:00 ET
|
Leap Therapeutics, Inc.
CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today presented promising...